J Infect Dis. 2000 Jan;181(1):358-63.

Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.

Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St Clair M, Sevin AD, Fox L, Chiozzi MH, Leonard JM, Rousseau F, D'Arc Roe J, Martinez A, Kessler H, Landay A.

Source

University of Colorado Health Sciences Center, Box B168, 4200 E. Ninth Ave., Denver, CO 80220, USA. liz.connick@uchsc.edu

Abstract

The effects of 1 year of zidovudine, lamivudine, and ritonavir treatment on immune reconstitution were evaluated in 34 human immunodeficiency virus (HIV)-infected individuals. After 48 weeks of therapy, 20 (59%) subjects had <100 copies HIV RNA/mL. CD4+ T cells increased from a median of 192/mm3 at baseline to 362/mm3 at week 48. Lymphocyte proliferative responses to Candida normalized within 12 weeks, but responses to HIV and tetanus remained depressed throughout therapy. Alloantigen responses increased within 12 weeks and then declined to baseline levels. Recovery of delayed-type hypersensitivity responses occurred after 12 weeks for Candida and after 48 weeks for mumps. The magnitude of virologic suppression was correlated with numeric increases in CD4+ T cells, but not with measures of functional immune reconstitution. Plasma virus suppression <100 copies/mL was not significantly correlated with increases in CD4+ T cells or functional immune reconstitution.

PMID:: 10608789; [PubMed - indexed for MEDLINE]

Free full text

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Related citations

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. [J Infect Dis. 1998]
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, et al. J Infect Dis. 1998 Jul; 178(1):70-9.
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. [Ann Intern Med. 2001]
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, et al. Ann Intern Med. 2001 Dec 4; 135(11):954-64.
Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. [AIDS. 2000]
Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.
Al-Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M, Landay A. AIDS. 2000 May 5; 14(7):761-70.
Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. [HIV Clin Trials. 2003]
Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
Ruane PJ, Parenti DM, Margolis DM, Shepp DH, Babinchak TJ, Van Kempen AS, Kauf TL, Danehower SA, Yau L, Hessenthaler SM, et al. HIV Clin Trials. 2003 Jul-Aug; 4(4):231-43.
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. [Clin Infect Dis. 2007]
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.
Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, Glesby M, Gulick R, Hicks C, Kessler H, et al. Clin Infect Dis. 2007 Mar 1; 44(5):749-54. Epub 2007 Jan 25.

See reviews... See all...

Cited by 16 PubMed Central articles

Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. [AIDS Res Hum Retroviruses. 2010]
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir.
Crawford KW, Spritzler J, Kalayjian RC, Parsons T, Landay A, Pollard R, Stocker V, Lederman MM, Flexner C, AIDS Clinical Trials Protocol 5015 Team. AIDS Res Hum Retroviruses. 2010 Jun; 26(6):635-43.
Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174. [AIDS Res Hum Retroviruses. 2010]
Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174.
Smith K, Zheng L, Bosch R, Margolis DM, Tenorio A, Napolitano L, Saag M, Connick E, Gross B, Francis I, et al. AIDS Res Hum Retroviruses. 2010 Apr; 26(4):425-32.
Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. [AIDS. 2008]
Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy.
Weinberg A, Dickover R, Britto P, Hu C, Patterson-Bartlett J, Kraimer J, Gutzman H, Shearer WT, Rathore M, McKinney R, et al. AIDS. 2008 Nov 12; 22(17):2267-77.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Immune reconstitution in the first year of potent antiretroviral therapy and its...
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.
J Infect Dis. 2000 Jan ;181(1):358-63.

PubMed
Risk of invasive cervical cancer among women with, or at risk for, HIV infection...
Risk of invasive cervical cancer among women with, or at risk for, HIV infection.
Int J Cancer. 1999 Jul 30 ;82(3):334-7.

PubMed
The GlycanBuilder: a fast, intuitive and flexible software tool for building and...
The GlycanBuilder: a fast, intuitive and flexible software tool for building and displaying glycan structures.
Source Code Biol Med. 2007 Aug 7 ;2:3.

PubMed
GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of g...
GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans.
J Proteome Res. 2008 Apr ;7(4):1650-9. Epub 2008 Mar 1 .

PubMed
Accreditation of the PGD laboratory.
Accreditation of the PGD laboratory.
Hum Reprod. 2010 Apr ;25(4):1051-65. Epub 2010 Jan 23 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Related citations

Cited by 16 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information